Class information for:
Level 1: VANDETANIB//NINTEDANIB//CEDIRANIB

Basic class information
Class id #P Avg. number of
references		 Database coverage
of references
18265 559 47.7 83%


Bar chart of Publication_year

Last years might be incomplete

Hierarchy of classes
The table includes all classes above and classes immediately below the current class.


Cluster id Level Cluster label #P
0 4 BIOCHEMISTRY & MOLECULAR BIOLOGY//CELL BIOLOGY//ONCOLOGY 4064930
518 3       ANGIOGENESIS//RETINOPATHY OF PREMATURITY//ENDOSTATIN 20826
361 2             ANGIOGENESIS//ENDOSTATIN//VEGF 17372
18265 1                   VANDETANIB//NINTEDANIB//CEDIRANIB 559

Terms with highest relevance score


rank Term termType Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with
term in
class
1 VANDETANIB authKW 1091012 10% 36% 56
2 NINTEDANIB authKW 617531 6% 36% 31
3 CEDIRANIB authKW 534132 5% 34% 29
4 ABT 869 authKW 349589 1% 80% 8
5 BIBF 1120 authKW 314621 2% 48% 12
6 AZD2171 authKW 287484 2% 53% 10
7 MOTESANIB authKW 218483 2% 40% 10
8 MULTI TARGETED TYROSINE KINASE INHIBITORS authKW 163871 1% 100% 3
9 VEGFR TKIS authKW 145661 1% 67% 4
10 ZD6474 authKW 137681 2% 23% 11

Web of Science journal categories


Rank Term Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with
term in
class
1 Oncology 12231 75% 0% 420
2 Respiratory System 779 10% 0% 57
3 Pharmacology & Pharmacy 659 22% 0% 122
4 Hematology 40 3% 0% 19
5 Medicine, Research & Experimental 4 2% 0% 13
6 Biotechnology & Applied Microbiology 2 3% 0% 14
7 Chemistry, Medicinal 1 1% 0% 7
8 Toxicology 0 1% 0% 6
9 Chemistry, Analytical 0 2% 0% 11
10 Integrative & Complementary Medicine 0 0% 0% 1

Address terms


Rank Term Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with
term in
class
1 THORAC HEAD NECK MED ONCOL CANC BIOL 72830 0% 67% 2
2 ADV TECHNOL TRANSLAT SCI 54624 0% 100% 1
3 AERODIGEST THORAC TUMOR PROGRAM 54624 0% 100% 1
4 AUO SAN LUIGI 54624 0% 100% 1
5 AUSTRALASIAN LUNG CANC TRIALS GRP 54624 0% 100% 1
6 BIOTECHNOL ONCOL 54624 0% 100% 1
7 BYDGOSZCZ CANC 54624 0% 100% 1
8 CANC MEDPHASE PROGRAM 1 54624 0% 100% 1
9 CITY MULTIPLE DISCIPLINE CLIN HOSP 54624 0% 100% 1
10 CLIN DISCOVERY MED ONCOL 54624 0% 100% 1

Journals


Rank Term Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with
term in
class
1 JOURNAL OF THORACIC ONCOLOGY 26443 6% 1% 36
2 CLINICAL LUNG CANCER 16163 3% 2% 15
3 INVESTIGATIONAL NEW DRUGS 8539 4% 1% 20
4 CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY 5236 3% 1% 14
5 JOURNAL OF CLINICAL ONCOLOGY 3641 6% 0% 33
6 FUTURE ONCOLOGY 3136 2% 1% 9
7 CANCER CHEMOTHERAPY AND PHARMACOLOGY 2953 4% 0% 20
8 ONCOTARGETS AND THERAPY 2846 2% 1% 10
9 EXPERT REVIEW OF ANTICANCER THERAPY 2682 2% 1% 9
10 CLINICAL CANCER RESEARCH 2653 5% 0% 27

Author Key Words


Rank Term Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with
term in
class		 LCSH search Wikipedia search
1 VANDETANIB 1091012 10% 36% 56 Search VANDETANIB Search VANDETANIB
2 NINTEDANIB 617531 6% 36% 31 Search NINTEDANIB Search NINTEDANIB
3 CEDIRANIB 534132 5% 34% 29 Search CEDIRANIB Search CEDIRANIB
4 ABT 869 349589 1% 80% 8 Search ABT+869 Search ABT+869
5 BIBF 1120 314621 2% 48% 12 Search BIBF+1120 Search BIBF+1120
6 AZD2171 287484 2% 53% 10 Search AZD2171 Search AZD2171
7 MOTESANIB 218483 2% 40% 10 Search MOTESANIB Search MOTESANIB
8 MULTI TARGETED TYROSINE KINASE INHIBITORS 163871 1% 100% 3 Search MULTI+TARGETED+TYROSINE+KINASE+INHIBITORS Search MULTI+TARGETED+TYROSINE+KINASE+INHIBITORS
9 VEGFR TKIS 145661 1% 67% 4 Search VEGFR+TKIS Search VEGFR+TKIS
10 ZD6474 137681 2% 23% 11 Search ZD6474 Search ZD6474

Core articles
The table includes core articles in the class. The following variables is taken into account for the relevance score of an article in a cluster c:
(1) Number of references referring to publications in the class.
(2) Share of total number of active references referring to publications in the class.
(3) Age of the article. New articles get higher score than old articles.
(4) Citation rate, normalized to year.


Rank Reference # ref.
in cl.		 Shr. of ref. in
cl.		 Citations
1 SKOURAS, VS , MARAGKOS, C , GRAPSA, D , SYRIGOS, KN , (2016) TARGETING NEOVASCULATURE WITH MULTITARGETED ANTIANGIOGENESIS TYROSINE KINASE INHIBITORS IN NON-SMALL CELL LUNG CANCER.BIODRUGS. VOL. 30. ISSUE 5. P. 421 -439 66 53% 0
2 HONG, SD , TAN, M , WANG, SZ , LUO, SY , CHEN, Y , ZHANG, L , (2015) EFFICACY AND SAFETY OF ANGIOGENESIS INHIBITORS IN ADVANCED NON-SMALL CELL LUNG CANCER: A SYSTEMATIC REVIEW AND META-ANALYSIS.JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY. VOL. 141. ISSUE 5. P. 909 -921 29 58% 14
3 PILOTTO, S , NOVELLO, S , PERETTI, U , KINSPERGHER, S , CIUFFREDA, L , MILELLA, M , CARBOGNIN, L , VAVALA, T , FERRARA, R , CACCESE, M , ET AL (2015) AN OVERVIEW OF ANGIOGENESIS INHIBITORS IN PHASE II STUDIES FOR NON-SMALL-CELL LUNG CANCER.EXPERT OPINION ON INVESTIGATIONAL DRUGS. VOL. 24. ISSUE 9. P. 1143 -1161 44 40% 0
4 GU, B , GAO, WC , CHU, HJ , GAO, J , FU, Z , DING, H , LV, JJ , WU, QQ , (2016) ADVERSE EVENTS RISK ASSOCIATED WITH ANTI-VEGFR AGENTS IN THE TREATMENT OF ADVANCED NONSMALL-CELL LUNG CANCER A META-ANALYSIS.MEDICINE. VOL. 95. ISSUE 48. P. - 28 56% 0
5 CHU, BF , OTTERSON, GA , (2016) INCORPORATION OF ANTIANGIOGENIC THERAPY INTO THE NON-SMALL-CELL LUNG CANCER PARADIGM.CLINICAL LUNG CANCER. VOL. 17. ISSUE 6. P. 493 -506 40 39% 0
6 LAMMERS, PE , HORN, L , (2013) TARGETING ANGIOGENESIS IN ADVANCED NON-SMALL CELL LUNG CANCER.JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK. VOL. 11. ISSUE 10. P. 1235-1247 28 56% 4
7 CAGLEVIC, C , GRASSI, M , RAEZ, L , LISTI, A , GIALLOMBARDO, M , BUSTAMANTE, E , GIL-BAZO, I , ROLFO, C , (2015) NINTEDANIB IN NON-SMALL CELL LUNG CANCER: FROM PRECLINICAL TO APPROVAL.THERAPEUTIC ADVANCES IN RESPIRATORY DISEASE. VOL. 9. ISSUE 4. P. 164 -172 19 76% 3
8 GORI, B , RICCIARDI, S , FULVI, A , DEL SIGNORE, E , DE MARINIS, F , (2012) NEW ORAL MULTITARGETED ANTIANGIOGENICS IN NON-SMALL-CELL LUNG CANCER TREATMENT.FUTURE ONCOLOGY. VOL. 8. ISSUE 5. P. 559 -573 28 57% 4
9 RECK, M , KAISER, R , MELLEMGAARD, A , DOUILLARD, JY , ORLOV, S , KRZAKOWSKI, M , VON PAWEL, J , GOTTFRIED, M , BONDARENKO, I , LIAO, ML , ET AL (2014) DOCETAXEL PLUS NINTEDANIB VERSUS DOCETAXEL PLUS PLACEBO IN PATIENTS WITH PREVIOUSLY TREATED NON-SMALL-CELL LUNG CANCER (LUME-LUNG 1): A PHASE 3, DOUBLE-BLIND, RANDOMISED CONTROLLED TRIAL.LANCET ONCOLOGY. VOL. 15. ISSUE 2. P. 143 -155 15 48% 165
10 WANG, S , YANG, Z , WANG, Z , (2015) ARE VEGFR-TKIS EFFECTIVE OR SAFE FOR PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER?.ONCOTARGET. VOL. 6. ISSUE 20. P. 18206 -18223 27 53% 1

Classes with closest relation at Level 1


Rank Class id link
1 17657 BEVACIZUMAB//METASTATIC BREAST CANCER//APATINIB
2 727 SUNITINIB//METASTATIC RENAL CELL CARCINOMA//RENAL CELL CARCINOMA
3 14480 BEVACIZUMAB//OVARIAN CANCER//VEGF TRAP
4 683 NON SMALL CELL LUNG CANCER//VINORELBINE//GEMCITABINE
5 147 GEFITINIB//EGFR MUTATION//ERLOTINIB
6 35107 DIARYLAMIDE//DIARYLUREA//A375P
7 1475 VEGF//FLT 1//VEGF RECEPTORS
8 11421 ANILINOQUINAZOLINE//4 ANILINOQUINAZOLINE//VEGFR 2 INHIBITOR
9 23991 REGORAFENIB//N DESETHYL SUNITINIB//N DESMETHYL IMATINIB
10 13109 ANAPLASTIC THYROID CARCINOMA//ANAPLASTIC THYROID CANCER//LENVATINIB

Go to start page